Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18213635 | 0.89 | HTR1A (0.42) | OPRM1DRD3DRD2OPRD1OPRK1 | |
| SCHEMBL5039661 | 0.89 | HTR1A (0.42) | OPRM1DRD3DRD2OPRD1OPRK1 | |
| SCHEMBL1068540 | 0.86 | CYP3A4 (0.39) | TDP1OPRM1DRD3OPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL10947305 | 0.84 | KCNH2 (0.49) | MEN1KMT2ANPSR1OPRM1DRD3 | |
| SCHEMBL16935352 | 0.84 | TDP1 (0.37) | MEN1KMT2ANPSR1TDP1OPRM1 | |
| SCHEMBL5003993 | 0.83 | MEN1 (0.46) | MEN1KMT2ANPSR1TDP1OPRM1 | |
| SCHEMBL8723759 | 0.83 | SIGMAR1 (0.42) | MEN1KMT2AOPRM1DRD3DRD2 | |
| SCHEMBL28162081 | 0.82 | TDP1 (0.50) | MEN1KMT2ANPSR1TDP1OPRM1 | |
| SCHEMBL9619532 | 0.82 | SIGMAR1 (0.44) | MEN1KMT2AOPRM1DRD3DRD2 | |
| SCHEMBL2879292 | 0.82 | KCNH2 (0.47) | MEN1KMT2AOPRM1DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307239-A4 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2005-01-26 | — | — | EP | claimed |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2004-01-29 | — | — | US | claimed |
| EP-0949265-B1 | RADIOACTIVE TRANSITION METAL NITRIDE HETERO-COMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2003-05-07 | — | — | EP | claimed |
| EP-1307239-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 2003-05-07 | — | — | EP | claimed |
| US-20020048549-A1 | Radioactive transition metal nitride heterocomplex | DUATTI ADRIANO (IT) | 2002-04-25 | — | — | US | claimed |
| WO-2002009771-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-02-07 | — | — | WO | claimed |
| US-6270745-B1 | FROM A BIS(PHOSPHINOALKYL) SULFIDE OR AMINE | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2001-08-07 | — | — | US | claimed |
| EP-0949265-A1 | RADIOACTIVE TRANSITION METAL NITRIDE HETERO-COMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 1999-10-13 | — | — | EP | claimed |
| US-7445765-B2 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2008-11-04 | — | — | US | disclosed |
| EP-1307239-A4 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1307239-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-0949265-B1 | RADIOACTIVE TRANSITION METAL NITRIDE HETERO-COMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-20020048549-A1 | Radioactive transition metal nitride heterocomplex | DUATTI ADRIANO (IT) | 2002-04-25 | — | — | US | disclosed |
| WO-2002009771-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-02-07 | — | — | WO | disclosed |
| US-6270745-B1 | FROM A BIS(PHOSPHINOALKYL) SULFIDE OR AMINE | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-0949265-A1 | RADIOACTIVE TRANSITION METAL NITRIDE HETERO-COMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020048549-A1 | Radioactive transition metal nitride heterocomplex | SHBG, GNRHR, PRMT5 | MEN1 11/4885KMT2A 3630/4885NPSR1 29/4885 |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | SHBG, TNNT2, TNNI3 | MEN1 746/4885KMT2A 4818/4885NPSR1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.